• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体重调整肝素预防肥胖患者减重手术中急性静脉血栓栓塞的疗效和安全性:一项系统评价和荟萃分析

Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis.

作者信息

Ikesaka Rick, Delluc Aurélien, Le Gal Grégoire, Carrier Marc

机构信息

Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Département de Médecine Interne, EA3878, University of Brest, Brest, France.

出版信息

Thromb Res. 2014 Apr;133(4):682-7. doi: 10.1016/j.thromres.2014.01.021. Epub 2014 Jan 23.

DOI:10.1016/j.thromres.2014.01.021
PMID:24508449
Abstract

BACKGROUND

The bariatric surgical population is a particularly high risk population for VTE. It is unclear if standard (i.e. non-adjusted) thromboprophylaxis doses of low-molecular weight or unfractionated heparin provide adequate protection for obese patients undergoing bariatric surgery, or if higher doses are required. We sought to determine whether a weight based thromboprophylactic dosing regimen is safe and effective in the post-operative period for obese patients undergoing bariatric surgery.

METHODS

A systematic literature search strategy was conducted using MEDLINE, EMBASE, the Cochrane Register of Controlled Trials and all EBM Reviews. Pooled proportions for the different outcomes were calculated.

RESULTS

A total of 6 studies (1 RCT, 4 cohort studies and one quasi experimental trial) containing 1,858 patients were include in the systematic review. Post bariatric surgery patients receiving weight-adjusted prophylactic doses of heparin products, had an in hospital rate of VTE of 0.54% (95% CI: 0.2 to 1.0%) compared to 2.0% (95% CI: 0.1 to 6.4%) for those that did not weight adjust doses. Rates of major bleeding were similar for both groups: 1.6% (95% CI: 0.6 to 3.0%) for patients receiving weight-adjusted dosing compared to 2.3% (95% CI: 1.1% to 3.9%) for those receiving standard doses of heparin products.

CONCLUSIONS

Adjusting the dose of heparin products for thromboprophylaxis post-bariatric surgery seems to be associated with a lower rate of in hospital VTE compared to a strategy of not adjusting the dose, although this did not reach statistical significance. This practice does not lead to an increase in adverse major bleeding events.

摘要

背景

肥胖症手术人群是静脉血栓栓塞(VTE)的高危人群。目前尚不清楚标准(即未调整)剂量的低分子量肝素或普通肝素进行血栓预防,能否为接受肥胖症手术的肥胖患者提供足够的保护,或者是否需要更高剂量。我们试图确定基于体重的血栓预防给药方案对接受肥胖症手术的肥胖患者术后是否安全有效。

方法

采用医学主题词表(MEDLINE)、医学与健康领域数据库(EMBASE)、Cochrane对照试验注册库以及所有循证医学综述进行系统的文献检索策略。计算不同结局的合并比例。

结果

系统评价共纳入6项研究(1项随机对照试验、4项队列研究和1项半实验性试验),包含1858例患者。接受体重调整预防剂量肝素产品的肥胖症手术后患者,住院期间VTE发生率为0.54%(95%可信区间:0.2%至1.0%),而未进行体重调整剂量的患者为2.0%(95%可信区间:0.1%至6.4%)。两组大出血发生率相似:接受体重调整剂量的患者为1.6%(95%可信区间:0.6%至3.0%),接受标准剂量肝素产品的患者为2.3%(95%可信区间:1.1%至3.9%)。

结论

与不调整剂量的策略相比,肥胖症手术后调整肝素产品预防血栓形成的剂量,似乎与较低的住院VTE发生率相关,尽管这未达到统计学显著性。这种做法不会导致严重不良出血事件增加。

相似文献

1
Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis.体重调整肝素预防肥胖患者减重手术中急性静脉血栓栓塞的疗效和安全性:一项系统评价和荟萃分析
Thromb Res. 2014 Apr;133(4):682-7. doi: 10.1016/j.thromres.2014.01.021. Epub 2014 Jan 23.
2
Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery.药物干预预防接受减重手术人群的静脉血栓栓塞症。
Cochrane Database Syst Rev. 2022 Nov 22;11(11):CD013683. doi: 10.1002/14651858.CD013683.pub2.
3
Pentasaccharides for the prevention of venous thromboembolism.用于预防静脉血栓栓塞的五糖
Cochrane Database Syst Rev. 2016 Oct 31;10(10):CD005134. doi: 10.1002/14651858.CD005134.pub3.
4
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.下肢大截肢患者静脉血栓栓塞的一级预防
Cochrane Database Syst Rev. 2013 Dec 16(12):CD010525. doi: 10.1002/14651858.CD010525.pub2.
5
Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.对有静脉血栓栓塞风险的住院患者实施血栓预防的干预措施。
Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008201. doi: 10.1002/14651858.CD008201.pub3.
6
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair.在择期初次髋关节或膝关节置换术或髋部骨折修复中,直接凝血因子Xa抑制剂与低分子量肝素或维生素K拮抗剂用于预防静脉血栓栓塞的比较
Cochrane Database Syst Rev. 2025 Jan 27;1(1):CD011762. doi: 10.1002/14651858.CD011762.pub2.
7
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.接受化疗的门诊癌症患者静脉血栓栓塞的一级预防
Cochrane Database Syst Rev. 2016 Dec 1;12(12):CD008500. doi: 10.1002/14651858.CD008500.pub4.
8
Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.对有静脉血栓栓塞风险的住院内科和外科患者实施血栓预防的干预措施。
Cochrane Database Syst Rev. 2013 Jul 16(7):CD008201. doi: 10.1002/14651858.CD008201.pub2.
9
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.延长疗程的抗凝剂用于预防全髋关节或膝关节置换术后或髋部骨折修复后的静脉血栓栓塞。
Cochrane Database Syst Rev. 2016 Mar 30;3(3):CD004179. doi: 10.1002/14651858.CD004179.pub2.
10
Neuromuscular electrical stimulation for the prevention of venous thromboembolism.用于预防静脉血栓栓塞的神经肌肉电刺激
Cochrane Database Syst Rev. 2017 Nov 21;11(11):CD011764. doi: 10.1002/14651858.CD011764.pub2.

引用本文的文献

1
Factors associated with venous thromboembolic disease due to failed thromboprophylaxis.与因血栓预防失败导致的静脉血栓栓塞性疾病相关的因素。
Thromb J. 2023 Dec 6;21(1):120. doi: 10.1186/s12959-023-00566-4.
2
Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery.药物干预预防接受减重手术人群的静脉血栓栓塞症。
Cochrane Database Syst Rev. 2022 Nov 22;11(11):CD013683. doi: 10.1002/14651858.CD013683.pub2.
3
Efficacy and safety of pre-operative insertion of inferior vena cava filter in patients undergoing bariatric surgery: a systematic review.
术前下腔静脉滤器置入在接受减重手术患者中的疗效和安全性:系统评价。
J Thromb Thrombolysis. 2022 Oct;54(3):502-523. doi: 10.1007/s11239-022-02689-3. Epub 2022 Aug 12.
4
Hypercoagulopathy in Overweight and Obese COVID-19 Patients: a Single-Center Case Series.超重和肥胖的新冠肺炎患者的高凝状态:一项单中心病例系列研究
J Crit Care Med (Targu Mures). 2021 Nov 13;8(1):41-48. doi: 10.2478/jccm-2021-0032. eCollection 2022 Jan.
5
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome-A Single Center Prospective Study.依诺肝素预防重症肾病综合征静脉血栓栓塞的抗Xa活性——一项单中心前瞻性研究
J Clin Med. 2021 Dec 6;10(23):5709. doi: 10.3390/jcm10235709.
6
Expert opinion on the preoperative medical optimization of adults with diabetes undergoing metabolic surgery.成人糖尿病患者代谢手术术前医学优化的专家意见。
World J Diabetes. 2021 Oct 15;12(10):1587-1621. doi: 10.4239/wjd.v12.i10.1587.
7
[Thrombotic Risk and Covid-19: Review of Current Evidence for a Better Diagnostic and Therapeutic Approach].[血栓形成风险与新冠病毒病:关于更好的诊断和治疗方法的当前证据综述]
Arch Bronconeumol. 2021 Jan;57:55-64. doi: 10.1016/j.arbres.2020.07.033. Epub 2020 Aug 31.
8
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗:鸟瞰。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.
9
Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach.新型冠状病毒肺炎中的凝血障碍与血栓栓塞性疾病:对当前证据的综述以寻求更好的方法
J Thorac Dis. 2021 Feb;13(2):1239-1255. doi: 10.21037/jtd-20-3062.
10
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.美国血液学会 2021 年关于 COVID-19 患者抗凝血栓预防治疗的指南。
Blood Adv. 2021 Feb 9;5(3):872-888. doi: 10.1182/bloodadvances.2020003763.